Welcome to our dedicated page for Regeneron Pharmaceuticals SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regeneron’s drug-development disclosures often read like dense lab manuals—300+ pages packed with clinical trial statistics, antibody engineering diagrams, and profit-share math that even seasoned analysts find challenging. If you have ever searched “where can I find Regeneron’s quarterly earnings report 10-Q filing” or tried to untangle an 8-K announcing an FDA advisory-committee outcome, you know the hurdle.
Stock Titan removes that barrier. Our AI-powered summaries translate every Regeneron SEC filing into plain language, flagging why a VelociSuite breakthrough drives R&D spend higher or how a new Sanofi collaboration changes revenue guidance. Receive real-time alerts the moment a Regeneron insider trading Form 4 transaction posts, scan a concise breakdown of each Regeneron annual report 10-K simplified, and compare segment margins across successive Regeneron quarterly earnings report 10-Q filings. Key forms are one click away:
- Form 4: Track Regeneron executive stock transactions Form 4 and spot buying or selling trends by Dr. Schleifer and Dr. Yancopoulos.
- 10-K / 10-Q: Understand pipeline milestones, manufacturing capacity, and R&D outlays without wading through technical jargon.
- 8-K: See Regeneron 8-K material events explained—drug approvals, trial readouts, and royalty amendments—in minutes, not hours.
- DEF 14A: Review the Regeneron proxy statement executive compensation details including performance-based equity.
Whether you need Regeneron Form 4 insider transactions real-time, are “understanding Regeneron SEC documents with AI,” or want a quick Regeneron earnings report filing analysis before markets open, this page delivers every disclosure the instant EDGAR releases it—already distilled into actionable insights.
Regeneron Pharmaceuticals (REGN) director Christine A. Poon reported insider transactions. On 10/29/2025, she exercised 6,500 non-qualified stock options at $520.01 and sold shares in multiple trades: 650 at $652.68, 2,735 at $653.5, 1,915 at $654.42, 100 at $655.1, 712 at $656.5, and 388 at $657.29.
On 10/30/2025, she exercised an additional 2,712 options at $520.01. Following the reported transactions, she beneficially owned 5,064 shares, held directly.
Regeneron Pharmaceuticals (REGN) executive Andrew Murphy reported insider transactions. On 10/29/2025, he exercised 35,000 non‑qualified stock options at $555.67 per share (code M), acquiring common stock. To cover taxes, 32,490 shares were withheld at $648.82 (code F). On 10/30/2025, he made a bona fide gift of 1,538 shares (code G).
After these transactions, he beneficially owned 50,046 shares directly and 4,370 shares indirectly via a 401(k) plan. The exercised option, which was scheduled to expire on 12/16/2025 and vested in four annual installments, now has 0 remaining.
Regeneron Pharmaceuticals reported Q3 2025 results. Revenue was $3,754.3 million, slightly above last year’s $3,720.7 million. Net income rose to $1,460.0 million with diluted EPS of $13.62, up from $11.54.
Product sales softened while collaboration income grew. Net product sales were $1,587.7 million versus $1,946.4 million, reflecting lower U.S. EYLEA family sales ($1,111.2 million vs $1,536.9 million) and higher global Libtayo sales ($365.2 million vs $288.6 million). Collaboration revenue increased to $1,968.4 million from $1,660.1 million, including contributions from Sanofi and Bayer.
Year-to-date operating cash flow reached $3,808.2 million. The company repurchased 1.1 million shares in Q3 for $663.0 million (4.5 million shares for $2,785.3 million year-to-date) and declared a $0.88 quarterly dividend in October. Total assets were $40,169.4 million and stockholders’ equity was $30,957.8 million as of September 30, 2025.
Regeneron Pharmaceuticals (REGN) furnished a press release reporting financial and operating results for the quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1 and incorporated by reference into Item 2.02. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated into Securities Act filings unless specifically referenced.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
